한국임상수의학회지 (Journal of Veterinary Clinics)

  • 제34권1호
  • /
  • Pages.13-17
  • /
  • 2017
  • /
  • 1598-298X(pISSN)
  • /
  • 2384-0749(eISSN)
한국임상수의학회 (The Korean Society of Veterinary Clinics)
권호 표지
DOI QR코드

DOI QR Code

Clinical Application of Oclacitinib in Dogs with Atopic Dermatitis

  • Hong, Eun-Hyung (Veterinary Medical Center, College of Veterinary Medicine, Chungbuk National University) ;
  • Park, Seo-Jin (Veterinary Medical Center, College of Veterinary Medicine, Chungbuk National University) ;
  • Jung, Dong-In (Research Institute of Natural Science, College of Veterinary Medicine, Gyeongsang National University) ;
  • Kang, Ji-Houn (Veterinary Medical Center, College of Veterinary Medicine, Chungbuk National University) ;
  • Yang, Mhan-Pyo (Veterinary Medical Center, College of Veterinary Medicine, Chungbuk National University) ;
  • Kang, Byeong-Teck (Veterinary Medical Center, College of Veterinary Medicine, Chungbuk National University)
  • 투고 : 2017.01.13
  • 심사 : 2017.02.14
  • 발행 : 2017.02.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

This study evaluated the efficacy and safety to determine the therapeutic responses of oclacitinib in canine atopic dermatitis (CAD) and identified factors related to the therapeutic response. Overall, 13 dogs with CAD were treated with oclacitinib for 56 days. Owners and veterinarians assessed visual analog scale (VAS) scores of pruritus and dermatitis. The examined dogs were grouped according to treatment success and failure based on changes in the VAS scores. To identify factors related to the therapeutic responses of oclacitinib, signalments (breed, sex, age, and body weight), mean progression time of CAD, mean Owner and Veterinarian VAS scores at day 0, and preexisting infection rate were compared between the two groups. Among the 13 dogs, 7 (53.8%) met the criteria of treatment success. In the success group, the Owner VAS scores were significantly lower from day 6 to 56 compared with the score at day 0 (P < 0.05). Additionally, the Veterinarian VAS scores were significantly decreased at days 14 and 42 compared with the score at day 0 (P < 0.05). There were no changes in hematological indices after the administration of oclacitinib. The most common abnormality reported was otitis externa (30.8%), followed by pyoderma (23.1%), and vomiting (7.7%). Factors related to responses of oclacitinib were not identified. This study demonstrated that oclacitinib was safe and moderately effective in dogs with CAD. This is the first report of the clinical application of oclacitinib in South Korea.

키워드

참고문헌

  1. Cosgrove SB, Cleaver DM, King VL, Gilmer AR, Daniels AE, Wren JA, Stegemann MR. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol 2015; 26: 171-179. https://doi.org/10.1111/vde.12194
  2. Cosgrove SB, Wren JA, Cleaver DM, Martin DD, Walsh KF, Harfst JA, Follis SL, King VL, Boucher JF, Stegemann MR. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol 2013; 24: 479-e114. https://doi.org/10.1111/vde.12047
  3. Cosgrove SB, Wren JA, Cleaver DM, Walsh KF, Follis SL, Harfst JA, King VL, Tena JK, Stegemann MR. Selection of an efficacious dosing regimen of oclacitinib ($Apoquel^{(R)}$) for the control of atopic dermatitis in client-owned dogs using visual analog scale and CADESI Scores. Vet Dermatol 2013;24: 381.
  4. Cosgrove SB, Wren JA, Cleaver DM, Walsh KF, Follis SI, King VI, Tena JK, Stegemann MR. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib ($Apoquel^{(R)}$) in client-owned dogs with atopic dermatitis. Vet Dermatol 2013; 24: 587-597. https://doi.org/10.1111/vde.12088
  5. Favrot C, Steffan J, Seewald W, Picco F. A prospective study on the clinical features of chronic canine atopic dermatitis and its diagnosis. Vet Dermatol 2010; 21: 23-31. https://doi.org/10.1111/j.1365-3164.2009.00758.x
  6. Fleck T, Humphrey W, Coscarelli, Galvan B, Aleo M, Gonzales A, Shelly J, Mahabir S, Mccall R. Comparison of the Janus kinase (JAK) inhibitor, oclacitinib, and prednisolone in canine models of pruritus. Vet Dermatol 2012; 23 (Suppl 1): 38.
  7. Gadeyne C, Little P, King VL, Edwards N, Davis K, Stegemann MR. Efficacy of oclacitinib ($Apoquel^{(R)}$) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in clientowned dogs in Australia. Vet Dermatol 2014; 25: 512-518. https://doi.org/10.1111/vde.12166
  8. Gonzales AJ, Bowman JW, Fici GJ, Zhang M, Mann DW, Mitton-Fry M. Oclacitinib ($APOQUEL^{(R)}$) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther 2014; 37: 317-324. https://doi.org/10.1111/jvp.12101
  9. Gonzales AJ, Humphrey WR, Messamore JE, Fleck TJ, Fici GJ, Shelly JA, Teel JF, Bammert GF, Dunham SA, Fuller TE, McCall RB. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol 2013; 24: 48-53. https://doi.org/10.1111/j.1365-3164.2012.01098.x
  10. Griffin CE, DeBoer DJ. The ACVD task force on canine atopic dermatitis (XIV); clinical manifestations of canine atopic dermatitis. Vet Immunol Immunopathol 2001; 81: 255-269. https://doi.org/10.1016/S0165-2427(01)00346-4
  11. Halliwell R. Revised nomenclature for veterinary allergy. Vet Immunol Immunopathol 2006; 114: 207-208. https://doi.org/10.1016/j.vetimm.2006.08.013
  12. Hill PB, Lau P, Rybnicek J. Development of an ownerassessed scale to measure the severity of pruritus in dogs. Vet Dermatol 2007; 18: 301-308. https://doi.org/10.1111/j.1365-3164.2007.00616.x
  13. Lauffer F, Ring J. Target-oriented therapy: Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs 2016; 21: 81-89. https://doi.org/10.1517/14728214.2016.1146681
  14. Little PR, King VL, Davis KR, Cosgrove SB, Stegemann MR. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Vet Dermatol 2015; 26: 23-30. https://doi.org/10.1111/vde.12186
  15. Olivry T. New diagnostic criteria for canine atopic dermatitis. Vet Dermatol 2010; 21: 124-127. https://doi.org/10.1111/j.1365-3164.2009.00776.x
  16. Olivry T, Bizikova P. A systematic review of randomized controlled trials for prevention or treatment of atopic dermatitis in dogs: 2008-2011 update. Vet Dermatol 2013; 24: 97-117. https://doi.org/10.1111/j.1365-3164.2012.01088.x
  17. Olivry T, DeBoer DJ, Favrot C, Jackson HA, Mueller RS, Nuttall T, Prelaud P. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol 2010; 21: 233-248. https://doi.org/10.1111/j.1365-3164.2010.00889.x
  18. Olivry T, Marsella R, Iwasaki T, Mueller R. Validation of CADESI-03, a severity scale for clinical trials enrolling dogs with atopic dermatitis. Vet Dermatol 2007; 18: 78-86. https://doi.org/10.1111/j.1365-3164.2007.00569.x
  19. Olivry T, Steffan J, Fisch RD, Prelaud P, Guaguere E, Fontaine J, Carlotti DN. Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs. J Am Vet Med Assoc 2002; 221: 370-377. https://doi.org/10.2460/javma.2002.221.370
  20. Rybnicek J, Lau-Gillard PJ, Harvey R, Hill PB. Further validation of a pruritus severity scale for use in dogs. Vet Dermatol 2009; 20: 115-122. https://doi.org/10.1111/j.1365-3164.2008.00728.x
  21. Scott DW, Miller WH, Griffin CE. Dermatologic therapy. In: Muller and Kirk's Small Animal Dermatology, 6th ed. Philadelphia: W.B. Saunders. 2001; 207-274.